2021
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309gDOI: 10.1039/d1nr00309g
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619DOI: 10.1111/bcp.14619
2020
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130DOI: 10.1101/2020.05.01.20087130
2018
Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir (Conference Paper)
Savage, A., Ashcroft, S., Box, H., Sharp, J., Neary, M., Owen, A., & Rannard, S. (2018). Formulation of dual component solid drug nanoparticles for improved oral bioavailability of Darunavir and Ritonavir. In ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY Vol. 256. Retrieved from https://www.webofscience.com/
Box, H., Negri, C., Livermore, J., Whalley, S., Johnson, A., McEntee, L., . . . Hope, W. (2018). Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(5). doi:10.1128/AAC.02516-17DOI: 10.1128/AAC.02516-17
Negri, C. E., Johnson, A., McEntee, L., Box, H., Whalley, S., Schwartz, J. A., . . . Hope, W. W. (2018). Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.. The Journal of infectious diseases, 217(7), 1118-1127. doi:10.1093/infdis/jix479DOI: 10.1093/infdis/jix479
Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation. (Conference Paper)
Box, H., Sharp, J., Neary, M. G., Moss, D., Tatham, L., Savage, A., . . . Owen, A. (n.d.). Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.. In CROI. Boston, MA, USA.
2017
Box, H. J. (2017, March 17). In vitro Models to Describe the Pharmacokinetics and Pharmacodynamics of New and Existing Antifungal Agents.
2016
Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis (Journal article)
Box, H., Livermore, J., Johnson, A., McEntee, L., Felton, T. W., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 278-287. doi:10.1128/AAC.01364-15DOI: 10.1128/AAC.01364-15
2015
Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry (Journal article)
Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53DOI: 10.2217/pgs.15.53
2013
Safety pharmacology - Current and emerging concepts (Journal article)
Hamdam, J., Sethu, S., Smith, T., Alfirevic, A., Alhaidari, M., Atkinson, J., . . . Goldring, C. (2013). Safety pharmacology - Current and emerging concepts. TOXICOLOGY AND APPLIED PHARMACOLOGY, 273(2), 229-241. doi:10.1016/j.taap.2013.04.039DOI: 10.1016/j.taap.2013.04.039